Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18458647 | 0.85 | ALDH1A1 (0.44) | ALDH1A1LMNAHTTNPSR1CTSS | |
| SCHEMBL18458523 | 0.82 | ALDH1A1 (0.60) | ALDH1A1 | |
| SCHEMBL19631754 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL19631841 | 0.80 | MEN1 (0.34) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL21337271 | 0.79 | MEN1 (0.31) | ALDH1A1MEN1KMT2AKDM4EGRM2 | |
| SCHEMBL14279653 | 0.77 | ALDH1A1 (0.51) | ALDH1A1CTSS | |
| SCHEMBL19631843 | 0.76 | OPRM1 (0.34) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18458361 | 0.75 | KMT2A (0.38) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL14863638 | 0.73 | ALDH1A1 (0.62) | ALDH1A1KDM4E | |
| SCHEMBL8648555 | 0.71 | KDM4E (0.47) | ALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-01 | — | — | US | disclosed |
| EP-3328853-B1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-09-11 | — | — | EP | disclosed |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| WO-2017016669-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | ALDH1A1 1946/4885MEN1 4882/4885KMT2A 2699/4885 |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | ALDH1A1 1946/4885MEN1 4882/4885KMT2A 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.